# An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

> **NCT02325219** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 192 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** CNTO 1959 50 mg
- **DRUG:** CTNO 1959 100 mg
- **DRUG:** Placebo 50 mg
- **DRUG:** Placebo 100 mg

## Key facts

- **NCT ID:** NCT02325219
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-19
- **Primary completion:** 2016-03-02
- **Final completion:** 2019-02-08
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2020-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02325219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02325219, "An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02325219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*